Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Glutamate receptor ionotropic, NMDA 2C subunit (GluN2C/GRIN2C) is encoded by the GRIN2C gene and forms part of the heterotetrameric NMDA receptor complex in the brain[5][6]. These receptors are ligand-gated ion channels that mediate excitatory synaptic transmission by permitting calcium and sodium influx upon activation by glutamate and co-agonist glycine or D-serine[1][6]. The GluN2C subunit is critical for the receptor's ion selectivity, gating characteristics, and pharmacological profile. NMDA receptor dysfunctions have been linked to a variety of neurological and psychiatric diseases, making GluN2C a therapeutic target and focal point in drug development[3][5][6].
NMDA receptor antagonists block glutamate binding or channel opening, inhibiting excitatory neurotransmission\nChannel blockers inhibit Ca²⁺ influx through the receptor channel
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, NMDA 2C subunit (GluN2C (also GRIN2C, based on gene symbol)).